Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $8.7 million.

  • Heron Therapeutics' Accumulated Expenses rose 2.54% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 2.54%. This contributed to the annual value of $9.6 million for FY2024, which is 3.58% up from last year.
  • Heron Therapeutics' Accumulated Expenses amounted to $8.7 million in Q3 2025, which was up 35.19% from $6.5 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Accumulated Expenses ranged from a high of $16.3 million in Q2 2022 and a low of $6.5 million during Q1 2025.
  • Over the past 3 years, Heron Therapeutics' median Accumulated Expenses value was $8.7 million (recorded in 2025), while the average stood at $8.5 million.
  • In the last 5 years, Heron Therapeutics' Accumulated Expenses rose by 26.85% in 2022 and then slumped by 39.62% in 2023.
  • Heron Therapeutics' Accumulated Expenses (Quarterly) stood at $15.3 million in 2021, then fell by 12.10% to $13.4 million in 2022, then crashed by 31.25% to $9.2 million in 2023, then climbed by 3.58% to $9.6 million in 2024, then climbed by 2.54% to $8.7 million in 2025.
  • Its Accumulated Expenses was $8.7 million in Q3 2025, compared to $6.5 million in Q2 2025 and $6.5 million in Q1 2025.